Provided by Tiger Trade Technology Pte. Ltd.

Amylyx Pharmaceuticals

14.91
+0.60004.19%
Volume:225.20K
Turnover:3.30M
Market Cap:1.65B
PE:-9.74
High:15.01
Open:14.31
Low:13.96
Close:14.31
52wk High:17.49
52wk Low:3.11
Shares:110.54M
Float Shares:65.45M
Volume Ratio:0.39
T/O Rate:0.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5305
EPS(LYR):-1.5305
ROE:-61.59%
ROA:-36.41%
PB:5.40
PE(LYR):-9.74

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies

Reuters
·
Dec 06, 2025

BUZZ-Amylyx rises after promising early-stage trial for ALS drug

Reuters
·
Dec 05, 2025

BRIEF-Amylyx Pharmaceuticals Announces New Safety And Tolerability Cohort 1 Data Of Amx0114

Reuters
·
Dec 05, 2025

Amylyx Reports Positive Early Safety Data for AMX0114 in ALS Phase 1 LUMINA Trial

Reuters
·
Dec 05, 2025

Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of Amx0114 in ALS From First-in-Human Lumina Trial

THOMSON REUTERS
·
Dec 05, 2025

Amylyx Pharmaceuticals Inc - Amx0114 Well-Tolerated With No Serious Adverse Events

THOMSON REUTERS
·
Dec 05, 2025

Amylyx Pharmaceuticals Chief Medical Officer Camille L. Bedrosian Reports Disposal of Common Shares

Reuters
·
Dec 04, 2025

Amylyx Pharmaceuticals Q3 EPS USD -0.37 Vs. IBES Estimate USD -0.47

Reuters
·
Nov 20, 2025

Is Amylyx (AMLX) Reshaping Its Investment Case With Improved Losses and Avexitide’s Path to Market?

Simply Wall St.
·
Nov 14, 2025

Stock Track | Amylyx Pharmaceuticals Soars Nearly 7% as Mizuho Boosts Price Target

Stock Track
·
Nov 10, 2025

Stock Track | Amylyx Pharmaceuticals Soars 5.61% Pre-Market as Mizuho Raises Target Price

Stock Track
·
Nov 10, 2025

Stock Track | Amylyx Pharmaceuticals Surges 5.61% Pre-Market on Mizuho's Target Price Hike

Stock Track
·
Nov 10, 2025

Assessing Amylyx Pharmaceuticals (AMLX) Valuation Following Recent Share Price Momentum

Simply Wall St.
·
Nov 09, 2025

Amylyx Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 08, 2025

Amylyx Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $20 From $16

THOMSON REUTERS
·
Nov 07, 2025

Should Amylyx Pharmaceuticals' Sharply Reduced Net Losses Prompt a Rethink by AMLX Investors?

Simply Wall St.
·
Nov 07, 2025

Amylyx Pharma Q3 loss narrows

Reuters
·
Nov 06, 2025

Amylyx Pharmaceuticals Reports Third Quarter 2025 Results and Extends Cash Runway Into 2028

Reuters
·
Nov 06, 2025

BRIEF-Amylyx Pharmaceuticals Q3 EPS USD -0.37 Vs. IBES Estimate USD -0.47

Reuters
·
Nov 06, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 06, 2025